Madrigal Pharmaceuticals, Inc.
MDGL
Kedudukan dalam Saham
#2014
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical... Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Harga Saham
$446.50
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$10.32B
Perubahan (1 hari)
-0.72%
Perubahan (1 tahun)
1.48%
Negara
US
Perdagangan Madrigal Pharmaceuticals, Inc. (MDGL)
Kategori
Healthcare
Sejarah pecahan saham untuk Madrigal Pharmaceuticals, Inc. (MDGL)
Saham Madrigal Pharmaceuticals, Inc. (simbol: MDGL) telah mengalami sejumlah 1 pecahan saham.
Pecahan saham terkini berlaku pada Jul 25, 2016.
Satu saham MDGL yang dibeli sebelum Jul 25, 2016 kini bersamaan dengan 0.028571428571429 saham MDGL.
Pecahan saham terkini berlaku pada Jul 25, 2016.
Satu saham MDGL yang dibeli sebelum Jul 25, 2016 kini bersamaan dengan 0.028571428571429 saham MDGL.
Senarai pecahan saham
| Tahun | Pecahan | Gandaan | Gandaan Kumulatif |
|---|---|---|---|
| 2016-07-25 | 1:35 | x0.028571428571429 | x0.028571428571429 |
Pecahan saham untuk syarikat pesaing atau serupa
| Syarikat | Bilangan pecahan saham | Gandaan Kumulatif | Negara |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
